MedTrace Logo

Triglyceride-Glucose and TGI-BMI Indices Compared With HOMA-IR

NCT07260201 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-12-03

No results posted yet for this study

Summary

Insulin resistance plays a key role in the development of type 2 diabetes, metabolic syndrome, and heart disease. The most common way to measure insulin resistance is the HOMA-IR index, but it requires fasting insulin tests, which are not always available in clinical practice.

This study aims to assess two simpler and more accessible alternatives: the triglyceride-glucose index (TGI) and its body mass index-adjusted version (TGI-BMI). Data from 150 adult patients were analyzed retrospectively and divided into groups according to their insulin resistance status. Standard laboratory and body measurements were compared between groups, and statistical analyses were used to determine how well TGI and TGI-BMI identify insulin resistance.

The results showed that both TGI and TGI-BMI were closely related to insulin resistance and demonstrated high diagnostic accuracy, similar to HOMA-IR. The TGI-BMI index was particularly effective in individuals with obesity. These findings suggest that TGI and TGI-BMI could serve as practical, low-cost alternatives to HOMA-IR for evaluating insulin resistance in clinical and population settings where insulin testing is not routinely available.

Conditions

Sponsors & Collaborators

  • Hisar Intercontinental Hospital

    lead OTHER

Principal Investigators

  • Bekir Sami Uyanık, MD, Prof · Hisar Intercontinental Hospital

  • Selami Aydin, MD · Hisar Intercontinental Hospital

  • Süleyman İpekci, Prof · Hisar Intercontinental Hospital and Atlas University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-10-20
Completion
2025-10-27

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07260201 on ClinicalTrials.gov